LGALS1 and myelofibrosis: We identified the β-galactoside binding protein galectin-1 as a striking biomarker of progression to myelofibrosis and poor survival in multiple patient cohorts, and as a promising therapeutic target, with reduced myeloproliferation and fibrosis in vitro and in vivo and improved survival following galectin-1 inhibition.